Synopsis Chronic hepatitis C (HCV) infection affects more than 10 million people in Asian countries and has thus been a major health. In India, the estimated prevalence of HCV is 0.5%–1.5%. The prevalence of HCV ranges from 0·1% to 1·1% in China and Southeast Asian countries including Malaysia, Thailand, Vietnam, and Singapore, accompanied by varying regional distribution of HCV genotypes. This ‘MED FACT’ discusses a research study entitled ‘’Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: A single-arm, open-label, phase 3 trial’’ , from The Lancet Gastroenterology & Hepatology.
Authors: Wei L, Lim SG, Xie Q, Văn KN, et. al. What was the need for this study? A combined regimen of sofosbuvir and velpatasvir had resulted in elevated sustained virologic response (SVR) rate in patients infected with chronic HCV with genotypes 1 to 6 in clinical trials.…
